INOGEN INC (INGN)

US45780L1044 - Common Stock

9.62  +0.43 (+4.68%)

After market: 9.62 0 (0%)

Fundamental Rating

3

Overall INGN gets a fundamental rating of 3 out of 10. We evaluated INGN against 187 industry peers in the Health Care Equipment & Supplies industry. INGN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INGN is valued expensive and it does not seem to be growing.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year INGN has reported negative net income.
In the past year INGN had a positive cash flow from operations.
INGN had negative earnings in 4 of the past 5 years.
In multiple years INGN reported negative operating cash flow during the last 5 years.

1.2 Ratios

INGN has a Return On Assets (-17.21%) which is in line with its industry peers.
Looking at the Return On Equity, with a value of -28.42%, INGN is in line with its industry, outperforming 57.53% of the companies in the same industry.
Industry RankSector Rank
ROA -17.21%
ROE -28.42%
ROIC N/A
ROA(3y)-17.8%
ROA(5y)-9.99%
ROE(3y)-26.63%
ROE(5y)-15.09%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of INGN (44.22%) is worse than 63.44% of its industry peers.
INGN's Gross Margin has declined in the last couple of years.
INGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.22%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.59%
GM growth 5Y-4.25%

More info and screens

6

2. Health

2.1 Basic Checks

INGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INGN has been increased compared to 1 year ago.
Compared to 5 years ago, INGN has more shares outstanding
There is no outstanding debt for INGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of 1.42, we must say that INGN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.42, INGN is in line with its industry, outperforming 50.00% of the companies in the same industry.
There is no outstanding debt for INGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.42
ROIC/WACCN/A
WACC9.21%

2.3 Liquidity

A Current Ratio of 2.66 indicates that INGN has no problem at all paying its short term obligations.
INGN's Current ratio of 2.66 is in line compared to the rest of the industry. INGN outperforms 50.00% of its industry peers.
A Quick Ratio of 2.34 indicates that INGN has no problem at all paying its short term obligations.
The Quick ratio of INGN (2.34) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.34

More info and screens

3

3. Growth

3.1 Past

The earnings per share for INGN have decreased by -9.76% in the last year.
Looking at the last year, INGN shows a small growth in Revenue. The Revenue has grown by 1.10% in the last year.
INGN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.49% yearly.
EPS 1Y (TTM)-9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)1.1%
Revenue growth 3Y0.77%
Revenue growth 5Y-2.49%
Sales Q2Q%5.8%

3.2 Future

INGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.84% yearly.
Based on estimates for the next years, INGN will show a small growth in Revenue. The Revenue will grow by 4.74% on average per year.
EPS Next Y41.41%
EPS Next 2Y22%
EPS Next 3Y14.84%
EPS Next 5YN/A
Revenue Next Year4.04%
Revenue Next 2Y4.3%
Revenue Next 3Y4.74%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INGN. In the last year negative earnings were reported.
Also next year INGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

INGN's earnings are expected to grow with 14.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22%
EPS Next 3Y14.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOGEN INC

NASDAQ:INGN (1/3/2025, 8:00:02 PM)

After market: 9.62 0 (0%)

9.62

+0.43 (+4.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners95.93%
Inst Owner Change-7.02%
Ins Owners1.41%
Ins Owner Change0%
Market Cap229.15M
Analysts51.11
Price Target10.2 (6.03%)
Short Float %3.26%
Short Ratio3.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)53.66%
Min EPS beat(2)50.49%
Max EPS beat(2)56.83%
EPS beat(4)3
Avg EPS beat(4)12.07%
Min EPS beat(4)-78.82%
Max EPS beat(4)56.83%
EPS beat(8)5
Avg EPS beat(8)15.6%
EPS beat(12)7
Avg EPS beat(12)10.96%
EPS beat(16)11
Avg EPS beat(16)51.89%
Revenue beat(2)2
Avg Revenue beat(2)4.5%
Min Revenue beat(2)3.51%
Max Revenue beat(2)5.48%
Revenue beat(4)3
Avg Revenue beat(4)2.37%
Min Revenue beat(4)-3.35%
Max Revenue beat(4)5.48%
Revenue beat(8)3
Avg Revenue beat(8)-1.32%
Revenue beat(12)6
Avg Revenue beat(12)-0.21%
Revenue beat(16)10
Avg Revenue beat(16)1.71%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.58%
EPS NY rev (1m)0%
EPS NY rev (3m)10.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.71%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.69
P/FCF N/A
P/OCF 39.59
P/B 1.24
P/tB 1.62
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-1.53
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)0.24
OCFY2.53%
SpS13.92
BVpS7.78
TBVpS5.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -17.21%
ROE -28.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.22%
FCFM N/A
ROA(3y)-17.8%
ROA(5y)-9.99%
ROE(3y)-26.63%
ROE(5y)-15.09%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.59%
GM growth 5Y-4.25%
F-Score6
Asset Turnover1.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 96.15%
Cap/Sales 6.11%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.34
Altman-Z 1.42
F-Score6
WACC9.21%
ROIC/WACCN/A
Cap/Depr(3y)116.78%
Cap/Depr(5y)93.93%
Cap/Sales(3y)6.97%
Cap/Sales(5y)5.51%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-9.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y41.41%
EPS Next 2Y22%
EPS Next 3Y14.84%
EPS Next 5YN/A
Revenue 1Y (TTM)1.1%
Revenue growth 3Y0.77%
Revenue growth 5Y-2.49%
Sales Q2Q%5.8%
Revenue Next Year4.04%
Revenue Next 2Y4.3%
Revenue Next 3Y4.74%
Revenue Next 5YN/A
EBIT growth 1Y-6.87%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.72%
EBIT Next 3Y23.4%
EBIT Next 5YN/A
FCF growth 1Y59.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y137.2%
OCF growth 3YN/A
OCF growth 5YN/A